NCT07016750View on ClinicalTrials.gov

A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa

PHASE3RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

KB803

Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein

DRUG

Placebo

Vehicle

Trial Locations (4)

45229

NOT_YET_RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

78218

RECRUITING

Texas Dermatology and Laser Specialists, San Antonio

92688

RECRUITING

Mission Dermatology Center, Rancho Santa Margarita

01605

NOT_YET_RECRUITING

UMass Memorial Medical Center, Worcester

Sponsors
All Listed Sponsors
lead

Krystal Biotech, Inc.

INDUSTRY

NCT07016750 - A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa | Biotech Hunter | Biotech Hunter